The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•10 March 2026•

1 min read

Gerresheimer Delays 2025 Results Amid Probe, Faces SDAX Index Removal

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1German medical products maker Gerresheimer delayed the release of its 2025 financial statements until June.

2The delay is attributed to an ongoing probe into the company's business deals.

German medical packaging manufacturer Gerresheimer has announced a second postponement of its 2025 annual financial results, now rescheduled for June. The delay stems from an ongoing investigation into specific business transactions, which has prevented the timely finalization of its accounts. Consequently, Deutsche Boerse will remove the company from the SDAX index in accordance with transparency and reporting regulations. This exclusion is expected to trigger significant selling pressure from passive funds and ETFs tracking the index. Investors remain concerned about the potential findings of the probe and its impact on corporate governance. The stock is likely to face continued volatility until the investigation concludes and financial clarity is restored.